Dr. Naissan Wesley - Dermatology Research in Beverly Hills
Dr. Naissan Wesley, an internationally recognized cosmetic and surgical dermatologist, has published more than 30 peer-reviewed medical journal articles. She has been involved in clinical trials for injectable treatments, including dermal fillers such as Juvederm Voluma®, fat-reducing treatments such as Kybella®, and muscle-relaxing botulinum toxins such as Dysport® and Xeomin®.
Having extensively studied ethnic skin, she is considered a leading expert on skin of color, and has published chapters in textbooks frequently referenced by both students and fellow dermatologists.
Evolus_CLIN001 — Co-investigator; A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines.
Evolus_CLIN004 — Co-investigator; A multicenter open label, multi dose, phase II trial to demonstrate the safety of DWP-450 in adult subjects for treatment of moderate to severe glabellar lines.
Xeomin® — Co-investigator; A prospective, multicenter, randomized, double-blinded, parallel group trial to investigate the equivalence of incobotulinumtoxinA (Xeomin®) to onabotulinumtoxinA (BOTOX®) in the treatment of glabellar frown lines, Merz.
ATX-101 (Kybella®) — Co-Investigator; Trial to evaluate efficacy of a novel injectable drug for the reduction of localized fat, Kythera.
Voluma® — Co-Investigator; Trial to evaluate efficacy of a novel filler to treat mid-face volume loss, Allergan.
Galderma RD.06.CIP.18156 (Emervel) — Co-Investigator; Trial to evaluate efficacy of a novel filler for correction of nasolabial folds, Galderma.
Cellutions — Co-Investigator; U.S. Pilot Study of Cellutions Nanopulse Therapy for Reduction in the Appearance of Cellulite.
Revance — Sub-Investigator; Pilot study for use of a topical botulinum toxin for periorbital rhytids.
Merz — Sub-Investigator; A prospective, randomized, double-blind, placebo-controlled, multicenter trial to investigate the efficacy and safety of NT 201 (Xeomin®), free of complexing proteins, in the treatment of glabellar frown lines.
Ulthera® — Sub-Investigator; A rater-blinded prospective clinical study of skin tightening after transcutaneous ultrasound energy delivery to the forehead and cheek skin.
Shazer — Sub-Investigator; Safety and efficacy trial of a personal light-based (7 J/cm2, 30ms, 650-1200nm) hair reduction system.
Zeltiq (CoolSculpting®)— Sub-Investigator; A prospective clinical study of non-invasive cooling of subcutaneous fat.
Artes Medical — Sub-Investigator; Post-Approval Study of ArteFill® for Correction of Nasolabial Folds.
Medicis — Sub-Investigator; A Phase 3-4 Multicenter, Open label Extension Study to Assess the Long-Term Safety of Repeat Administrations of Reloxin (Dysport®) in the Treatment of Glabellar Lines. Protocol 732
Syneron — Sub-Investigator; Clinical evaluation of skin laxity, subcutaneous fat, and cellulite treated with VelaShape®: a device that delivers infrared, radiofrequency energy, and vacuum suctioning to the abdomen, buttocks, and thighs.
Miramar Labs (miraDry®) — Sub-Investigator; Clinical Evaluation of the DTS (microwave energy delivery system) for treatment of hyperhidrosis - a feasibility study.
Thermage® — Sub-Investigator; An open label trial to determine the efficacy of Thermage® Multiplex Tip for the treatment of circumferential upper arm tissue.
Nomir — Sub-Investigator; Noveon Laser Treatment of Onychomycosis: A device performance pivotal trial.